AstraZeneca, Sanofi RSV treatment Beyfortus endorsed by CDC panel (updated)
GOLFX/iStock via Getty Images

Editor's note: This article was updated at 2:55p ET to reflect a CDC panel vote

Beyfortus (nirsevimab), a biologic to prevent respiratory syncytial virus (RSV) in infants from AstraZeneca (NASDAQ:AZN) and Sanofi (NASDAQ:SNY), has been endorsed by a panel of CDC advisors.

Per a presentation made Thursday at a meeting of the Advisory Committee on Immunization Practices, Beyfortus will have a suggested list price of $495 per shot.
While Beyfortus was approved by the US FDA last month, the ACIP meeting on Thursday was to determine whether or not to endorse the treatment for infants and babies up to two years old.

More on Beyfortus

Sanofi to get commercial control of RSV therapy nirsevimab in US, AstraZeneca to record $0.7B gain
RSV treatment market to surge past $9B by 2029